+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cystic Fibrosis Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Pancreatic Enzyme Supplements), Route of Administration (Oral), Distribution Channel, Region, and Segment Forecasts, 2025-2030

  • PDF Icon

    Report

  • 90 Pages
  • October 2024
  • Region: Global
  • Grand View Research
  • ID: 6024694
The global cystic fibrosis therapeutics market size is estimated to reach USD 22.7 billion by 2030, expanding at a CAGR of 14.2% from 2025 to 2030. The rising prevalence of Cystic Fibrosis (CF) globally, research & development activities undertaken by key players, and favorable initiatives undertaken by nonprofit organizations are expected to boost the market over the forecast period.

The rising prevalence of CF indicates the rising demand for treatment alternatives, thereby uplifting the market. The key players operating in this market in collaboration with nonprofit organizations focus on the development of novel therapeutics for treatment. Some of the drugs that are under clinical studies are VX-445 + tezacaftor + ivacaftor, PTI-428, QR-010, AZD5634, and POL6014.

Favorable initiatives taken by regional and national nonprofit organizations is one of the key factors propelling growth. These initiatives ensure support to CF patients. These organizations aid in research & development activities of these therapeutics and help improve the quality of life of these patients. For instance, North American Cystic Fibrosis Conference (NACFC) was formed in 1986 to provide a collaborative and educational forum to CF professionals to share advances in R&D related to CF therapeutics.

Cystic Fibrosis Therapeutics Market Report Highlights

  • The global CF therapeutics market size was estimated at USD 10.3 billion in 2024 and is expected to grow at a CAGR of 14.2% from 2025 to 2030
  • CFTR modulators dominated the market and accounted for the largest revenue share of 44.0% in 2024 owing to the approval of CFTR modulator, Orkambi and the presence of various investigational compounds under the pipeline.
  • The growth of oral administration led the market and accounted for the largest revenue share of 69.0% in 2024 due to the ease of administration and convenience
  • North America accounted for the largest market share owing to the presence of Caucasian descents in this region. Improved healthcare infrastructure, reimbursements, and initiatives undertaken by the nonprofit organizations is expected to propel the market over forecast period,
  • The key players include AbbVie Inc., F. Hoffmann-La Roche Ltd.; Gilead, Novartis AG, Vertex Pharmaceuticals Inc., AIT (Advanced Inhalation Therapies), Alaxia, Teva Pharmaceutical Industries Ltd, Merck & Co. Inc., Alcresta Therapeutics Inc., Allergan, and AstraZeneca

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments
  • Competitive Landscape: Explore the market presence of key players worldwide
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

The leading players in the Cystic Fibrosis Therapeutics market include:

  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd
  • Gilead
  • Novartis AG
  • Vertex Pharmaceuticals Incorporated
  • AIT (Advanced Inhalation Therapies)
  • Alaxia
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co. Inc.
  • Sionna Therapeutics
  • Alcresta Therapeutics, Inc.
  • AstraZeneca


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Route of Administration
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Cystic Fibrosis Therapeutics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Cystic Fibrosis Therapeutics Market: Drug Class Business Analysis
4.1. Drug Class Market Share, 2024 & 2030
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. CFTR Modulators
4.4.1. CFTR Modulators Market, 2018 - 2030 (USD Million)
4.5. Pancreatic Enzyme Supplements
4.5.1. Pancreatic Enzyme Supplements Market, 2018 - 2030 (USD Million)
4.6. Mucolytics
4.6.1. Mucolytics Market, 2018 - 2030 (USD Million)
4.7. Bronchodilators
4.7.1. Bronchodilators Market, 2018 - 2030 (USD Million)
Chapter 5. Cystic Fibrosis Therapeutics Market: Route of Administration Business Analysis
5.1. Route of Administration Market Share, 2024 & 2030
5.2. Route of Administration Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
5.4. Oral
5.4.1. Oral Market, 2018 - 2030 (USD Million)
5.5. Inhaled
5.5.1. Inhaled Market, 2018 - 2030 (USD Million)
Chapter 6. Cystic Fibrosis Therapeutics Market: Distribution Channel Business Analysis
6.1. Distribution Channel Market Share, 2024 & 2030
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Hospital Pharmacies
6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
6.6. Online Pharmacies
6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)
Chapter 7. Cystic Fibrosis Therapeutics Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. Competitive Insights
7.4.2.4. U.S. Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Competitive Insights
7.4.3.4. Canada Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Regulatory Framework
7.4.4.3. Competitive Insights
7.4.4.4. Mexico Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Europe
7.5.1. Europe Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. Competitive Insights
7.5.2.4. UK Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Insights
7.5.3.4. Germany Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Insights
7.5.4.4. France Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Insights
7.5.5.4. Italy Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Competitive Insights
7.5.6.4. Spain Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.7. Norway
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework
7.5.7.3. Competitive Insights
7.5.7.4. Norway Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.8. Denmark
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework
7.5.8.3. Competitive Insights
7.5.8.4. Denmark Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.9. Sweden
7.5.9.1. Key Country Dynamics
7.5.9.2. Regulatory Framework
7.5.9.3. Competitive Insights
7.5.9.4. Sweden Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Competitive Insights
7.6.2.4. Japan Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Insights
7.6.3.4. China Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Insights
7.6.4.4. India Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Insights
7.6.5.4. South Korea Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.6. Australia
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Insights
7.6.6.4. Australia Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Regulatory Framework
7.6.7.3. Competitive Insights
7.6.7.4. Thailand Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Competitive Insights
7.7.2.4. Brazil Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Competitive Insights
7.7.3.4. Argentina Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8. MEA
7.8.1. MEA Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. Competitive Insights
7.8.2.4. South Africa Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Competitive Insights
7.8.3.4. Saudi Arabia Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework
7.8.4.3. Competitive Insights
7.8.4.4. UAE Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamic
7.8.5.2. Regulatory Frameworks
7.8.5.3. Competitive Insights
7.8.5.4. Kuwait Cystic Fibrosis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. AbbVie Inc.
8.5.1.1. Company Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. F. Hoffmann-La Roche Ltd.
8.5.2.1. Company Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Gilead
8.5.3.1. Company Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Novartis AG
8.5.4.1. Company Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Vertex Pharmaceuticals Incorporated
8.5.5.1. Company Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. AIT (Advanced Inhalation Therapies)
8.5.6.1. Company Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Alaxia
8.5.7.1. Company Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Teva Pharmaceutical Industries Ltd.
8.5.8.1. Company Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Merck & Co. Inc.
8.5.9.1. Company Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Alcresta Therapeutics, Inc.
8.5.10.1. Company Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
8.5.11. AstraZeneca
8.5.11.1. Company Overview
8.5.11.2. Financial Performance
8.5.11.3. Product Benchmarking
8.5.11.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Cystic Fibrosis Therapeutics Market, by Region, 2018 - 2030 (USD Million)
Table 4 Global Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 5 Global Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 6 Global Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 7 North America Cystic Fibrosis Therapeutics Market, by Country, 2018 - 2030 (USD Million)
Table 8 North America Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 9 North America Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 10 North America Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 11 U.S. Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 12 U.S. Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 13 U.S. Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 14 Canada Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 15 Canada Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 16 Canada Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 17 Mexico Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 18 Mexico Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 19 Mexico Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 20 Europe Cystic Fibrosis Therapeutics Market, by Country, 2018 - 2030 (USD Million)
Table 21 Europe Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 22 Europe Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 23 Europe Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 24 UK Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 25 UK Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 26 UK Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 27 Germany Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 28 Germany Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 29 Germany Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 30 France Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 31 France Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 32 France Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 33 Italy Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 34 Italy Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 35 Italy Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 36 Spain Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 37 Spain Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 38 Spain Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 39 Norway Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 40 Norway Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 41 Norway Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 42 Denmark Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 43 Denmark Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 44 Denmark Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 45 Sweden Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 46 Sweden Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 47 Sweden Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 48 Asia Pacific Cystic Fibrosis Therapeutics Market, by Country, 2018 - 2030 (USD Million)
Table 49 Asia Pacific Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 50 Asia Pacific Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 51 Asia Pacific Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 52 Japan Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 53 Japan Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 54 Japan Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 55 China Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 56 China Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 57 China Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 58 India Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 59 India Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 60 India Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 61 Australia Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 62 Australia Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 63 Australia Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 64 South Korea Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 65 South Korea Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 66 South Korea Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 67 Thailand Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 68 Thailand Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 69 Thailand Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 70 Latin America Cystic Fibrosis Therapeutics Market, by Country, 2018 - 2030 (USD Million)
Table 71 Latin America Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 72 Latin America Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 73 Latin America Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 74 Brazil Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 75 Brazil Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 76 Brazil Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 77 Argentina Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 78 Argentina Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 79 Argentina Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 80 Middle East & Africa Cystic Fibrosis Therapeutics Market, by Country, 2018 - 2030 (USD Million)
Table 81 Middle East & Africa Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 82 Middle East & Africa Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 83 Middle East & Africa Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 84 South Africa Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 85 South Africa Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 86 South Africa Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 89 Saudi Arabia Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 90 UAE Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 91 UAE Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 92 UAE Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 93 Kuwait Cystic Fibrosis Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
Table 94 Kuwait Cystic Fibrosis Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 95 Kuwait Cystic Fibrosis Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Cystic Fibrosis Therapeutics Market Segmentation
Fig. 2 Market Research Process
Fig. 3 Data Triangulation Techniques
Fig. 4 Primary Research Pattern
Fig. 5 Market Research Approaches
Fig. 6 Value-chain-based Sizing & Forecasting
Fig. 7 Market Formulation & Validation
Fig. 8 Market Snapshot
Fig. 9 Segment Outlook
Fig. 10 Segment Outlook
Fig. 11 Competitive landscape
Fig. 12 Cystic Fibrosis Therapeutics Market Dynamics
Fig. 13 Cystic Fibrosis Therapeutics Market: Porter’s Five Forces Analysis
Fig. 14 Cystic Fibrosis Therapeutics Market: PESTLE Analysis
Fig. 15 Cystic Fibrosis Therapeutics Market: Drug Class Segment Dashboard
Fig. 16 Cystic Fibrosis Therapeutics Market: Drug Class Market Share Analysis, 2024 & 2030
Fig. 17 CFTR Modulators Market, 2018 - 2030 (USD Million)
Fig. 18 Pancreatic Enzyme Supplements Market, 2018 - 2030 (USD Million)
Fig. 19 Mucolytics Market, 2018 - 2030 (USD Million)
Fig. 20 Bronchodilators Market, 2018 - 2030 (USD Million)
Fig. 21 Cystic Fibrosis Therapeutics Market: Route of Administration Segment Dashboard
Fig. 22 Cystic Fibrosis Therapeutics Market: Route of Administration Market Share Analysis, 2024 & 2030
Fig. 23 Oral Market, 2018 - 2030 (USD Million)
Fig. 24 Inhaled Market, 2018 - 2030 (USD Million)
Fig. 25 Cystic Fibrosis Therapeutics Market: Distribution Channel Segment Dashboard
Fig. 26 Cystic Fibrosis Therapeutics Market: Distribution Channel Market Share Analysis, 2024 & 2030
Fig. 27 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
Fig. 28 Retail Pharmacies Laboratories Market, 2018 - 2030 (USD Million)
Fig. 29 Online Pharmacies Laboratories Market, 2018 - 2030 (USD Million)
Fig. 30 Cystic Fibrosis Therapeutics Market Revenue, by Region
Fig. 31 Regional Marketplace: Key Takeaways
Fig. 32 Regional Marketplace: Key Takeaways
Fig. 33 North America Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 34 U.S. Country Dynamics
Fig. 35 U.S. Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 36 Canada Country Dynamics
Fig. 37 Canada Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 38 Mexico Country Dynamics
Fig. 39 Mexico Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 40 Europe Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 41 UK Country Dynamics
Fig. 42 UK Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 43 Germany Country Dynamics
Fig. 44 Germany Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 45 France Country Dynamics
Fig. 46 France Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 47 Italy Country Dynamics
Fig. 48 Italy Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 49 Spain Country Dynamics
Fig. 50 Spain Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 51 Norway Country Dynamics
Fig. 52 Norway Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 53 Sweden Country Dynamics
Fig. 54 Sweden Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 55 Denmark Country Dynamics
Fig. 56 Denmark Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 57 Asia Pacific Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 58 Japan Country Dynamics
Fig. 59 Japan Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 60 China Country Dynamics
Fig. 61 China Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 62 India Country Dynamics
Fig. 63 India Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 64 Australia Country Dynamics
Fig. 65 Australia Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 66 South Korea Country Dynamics
Fig. 67 South Korea Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 68 Thailand Country Dynamics
Fig. 69 Thailand Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 70 Latin America Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 71 Brazil Country Dynamics
Fig. 72 Brazil Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 73 Argentina Country Dynamics
Fig. 74 Argentina Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 75 MEA Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 76 South Africa Country Dynamics
Fig. 77 South Africa Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 78 Saudi Arabia Country Dynamics
Fig. 79 Saudi Arabia Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 80 UAE Country Dynamics
Fig. 81 UAE Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 82 Kuwait Key Country Dynamics
Fig. 83 Kuwait Cystic Fibrosis Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 84 Company categorization
Fig. 85 Company market position analysis
Fig. 86 Strategic framework

Companies Mentioned

  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd
  • Gilead
  • Novartis AG
  • Vertex Pharmaceuticals Incorporated
  • AIT (Advanced Inhalation Therapies)
  • Alaxia
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co. Inc.
  • Sionna Therapeutics
  • Alcresta Therapeutics, Inc.
  • AstraZeneca

Methodology

Loading
LOADING...

Table Information